- Philstar.com
- The Philippine Star
- Pilipino Star Ngayon
- The Freeman
- Pang-Masa
- Banat
- Interaksyon
- Coupons
Array ( [results] => Array ( [0] => Array ( [ArticleID] => 1243290 [Title] => New drug helps people with advanced HER2-positive breast cancer live longer [Summary] =>Roche announced recently that trastuzumab emtansine significantly extended the time people with advanced HER2-positive breast cancer (metastatic and unresectable locally advanced/recurrent) lived without their disease worsening (progression-free survival), compared to people who received a treatment of their physician’s choice in an open-label phase III study called TH3RESA.
[DatePublished] => 2013-10-10 00:00:00 [ColumnID] => 0 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 731565 [Title] => Treatment for advanced ovarian cancer receives positive opinion [Summary] =>
BASEL, Switzerland — Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of bevacizumab in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer.
[DatePublished] => 2011-09-29 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [2] => Array ( [ArticleID] => 703067 [Title] => Roche's drug receives broader EU label for women with metastatic breast cancer [Summary] =>BASEL, Switzerland — Roche announced this week that the European Commission (EC) has extended the existing bevacizumab metastatic breast cancer label to include combination with capecitabine.
[DatePublished] => 2011-07-07 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [3] => Array ( [ArticleID] => 696213 [Title] => Roche drug halves risk of disease worsening in women with recurrent ovarian cancer [Summary] =>Roche recently announced the results from OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (gemcitabine and carboplatin) followed by the continued use of bevacizumab alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.
[DatePublished] => 2011-06-16 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [4] => Array ( [ArticleID] => 691717 [Title] => Roche announces new study data on rheumatoid arthritis treatment [Summary] =>Roche recently announced new data from the ACT-RAY study, presented at the European League Against Rheumatism congress.
[DatePublished] => 2011-06-02 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [5] => Array ( [ArticleID] => 689458 [Title] => Roche bares study results on lung cancer medicine [Summary] =>Roche announced this week the final results from a randomized, multi-center, double-blind Phase II study with its investigational personalized medicine, MetMAb, in people with previously treated advanced non-small cell lung cancer (NSCLC).
[DatePublished] => 2011-05-26 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [6] => Array ( [ArticleID] => 682217 [Title] => Roche drug for treating systemic juvenile idiopathic arthritis gets US FDA approval [Summary] =>The United States Food and Drug Administration (FDA) has approved Roche’s drug tocilizumab for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged two and older.
[DatePublished] => 2011-05-05 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [7] => Array ( [ArticleID] => 678152 [Title] => Roche bares positive results of breast cancer drug [Summary] =>BASEL, Switzerland — Roche has announced the topline results of its first randomized trial of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer.
[DatePublished] => 2011-04-21 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [8] => Array ( [ArticleID] => 671055 [Title] => Roche announces positive results for severe skin cancer medicine [Summary] =>BASEL, Switzerland — Roche announced this week that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib, showed positive results in people with advanced basal cell carcinoma (aBCC), a particularly severe and debilitating form of skin cancer.
[DatePublished] => 2011-03-31 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [9] => Array ( [ArticleID] => 657719 [Title] => Treatment helps women with ovarian cancer live significantly longer [Summary] =>Roche announced this week that OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of bevacizumab alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.
[DatePublished] => 2011-02-17 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
DR. HAL BARRON
Array ( [results] => Array ( [0] => Array ( [ArticleID] => 1243290 [Title] => New drug helps people with advanced HER2-positive breast cancer live longer [Summary] =>Roche announced recently that trastuzumab emtansine significantly extended the time people with advanced HER2-positive breast cancer (metastatic and unresectable locally advanced/recurrent) lived without their disease worsening (progression-free survival), compared to people who received a treatment of their physician’s choice in an open-label phase III study called TH3RESA.
[DatePublished] => 2013-10-10 00:00:00 [ColumnID] => 0 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 731565 [Title] => Treatment for advanced ovarian cancer receives positive opinion [Summary] =>
BASEL, Switzerland — Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of bevacizumab in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer.
[DatePublished] => 2011-09-29 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [2] => Array ( [ArticleID] => 703067 [Title] => Roche's drug receives broader EU label for women with metastatic breast cancer [Summary] =>BASEL, Switzerland — Roche announced this week that the European Commission (EC) has extended the existing bevacizumab metastatic breast cancer label to include combination with capecitabine.
[DatePublished] => 2011-07-07 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [3] => Array ( [ArticleID] => 696213 [Title] => Roche drug halves risk of disease worsening in women with recurrent ovarian cancer [Summary] =>Roche recently announced the results from OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (gemcitabine and carboplatin) followed by the continued use of bevacizumab alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.
[DatePublished] => 2011-06-16 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [4] => Array ( [ArticleID] => 691717 [Title] => Roche announces new study data on rheumatoid arthritis treatment [Summary] =>Roche recently announced new data from the ACT-RAY study, presented at the European League Against Rheumatism congress.
[DatePublished] => 2011-06-02 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [5] => Array ( [ArticleID] => 689458 [Title] => Roche bares study results on lung cancer medicine [Summary] =>Roche announced this week the final results from a randomized, multi-center, double-blind Phase II study with its investigational personalized medicine, MetMAb, in people with previously treated advanced non-small cell lung cancer (NSCLC).
[DatePublished] => 2011-05-26 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [6] => Array ( [ArticleID] => 682217 [Title] => Roche drug for treating systemic juvenile idiopathic arthritis gets US FDA approval [Summary] =>The United States Food and Drug Administration (FDA) has approved Roche’s drug tocilizumab for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged two and older.
[DatePublished] => 2011-05-05 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [7] => Array ( [ArticleID] => 678152 [Title] => Roche bares positive results of breast cancer drug [Summary] =>BASEL, Switzerland — Roche has announced the topline results of its first randomized trial of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer.
[DatePublished] => 2011-04-21 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [8] => Array ( [ArticleID] => 671055 [Title] => Roche announces positive results for severe skin cancer medicine [Summary] =>BASEL, Switzerland — Roche announced this week that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib, showed positive results in people with advanced basal cell carcinoma (aBCC), a particularly severe and debilitating form of skin cancer.
[DatePublished] => 2011-03-31 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [9] => Array ( [ArticleID] => 657719 [Title] => Treatment helps women with ovarian cancer live significantly longer [Summary] =>Roche announced this week that OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of bevacizumab alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.
[DatePublished] => 2011-02-17 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
abtest
EZ2/LVM - 10 10
SUERTRES - 2 8 3
6D Lotto - 9 2 9 8 5 8
6/42 - 20 39 22 7 9 1
P23,586,438.00
Grand Lotto - 10 28 3 53 41 20
P40,549,068.00
- 12:00 am